MONTREAL, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. CMTA, a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare bone disorders and other diseases, today announced the company's participation at the following upcoming conferences:
American Society for Bone and Mineral Research (ASBMR) 2018
Clementia will present a poster detailing updated data from its Phase 2 clinical trial of palovarotene for the treatment of fibrodysplasia ossificans progressiva (FOP) at the ASBMR 2018 Annual Meeting.
Details are as follows:
Abstract Title: Palovarotene Reduces New Heterotopic Ossification in Fibrodysplasia Ossificans Progressiva (FOP) (Presentation Number: MON-1066)
Date and Time: Oct. 1, 2018 from 12:00 - 2:00 p.m. ET
Location: ASBMR Discovery Hall – Exhibit Hall 220 B-E
In addition, Clarissa Desjardins, Ph.D., chief executive officer and founder of Clementia, will present at the following investor conferences:
- The Morgan Stanley Annual Global Healthcare Conference in New York City on Wednesday, Sept. 12, 2018 at 3:40 p.m. ET
- The Leerink Partners 2018 Rare Disease Roundtable in New York City on Tuesday, Oct. 2, 2018 at 2:00 p.m. ET
Webcasts of the Morgan Stanley and Leerink Partners conference presentations will be available in the Investor Relations section of the company's website at www.clementiapharma.com. A replay of each webcast will be available for 30 days following the event.
About Clementia Pharmaceuticals Inc.
Clementia is a clinical-stage company innovating new treatments for people with ultra-rare bone disorders and other diseases with high medical need. The company's lead product candidate, palovarotene, a novel RARγ agonist, is currently being evaluated in the Phase 3 MOVE Trial to treat fibrodysplasia ossificans progressiva (FOP) and in the Phase 2 MO-Ped Trial to treat multiple osteochondromas (MO, also known as multiple hereditary exostoses/MHE). Clementia is also investigating palovarotene for the potential treatment of other conditions that may benefit from RARγ therapy. For more information, please visit www.clementiapharma.com and connect with us on Twitter @ClementiaPharma.
Investor/Media Contact:
Joseph Walewicz
Clementia Pharmaceuticals Inc.
+1-514-940-1080
Chelcie Lister
THRUST Strategic Communications
+1-910-777-3049
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.